	US 12,269,872 B2
	*Neutralizing antibodies to Plasmodium falciparum* circumsporozoite protein and their use**
Robert Seder, Chevy Chase, MD (US); Lawrence Wang, Bethesda, MD (US); Rachel Vistein, Bethesda, MD (US); and Joseph Francica, Bethesda, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Appl. No. 17/608,381
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
PCT Filed May 4, 2020, PCT No. PCT/US2020/031345 § 371(c)(1), (2) Date Nov. 2, 2021, PCT Pub. No. WO2020/227228, PCT Pub. Date Nov. 12, 2020.
Claims priority of provisional application 62/842,590, filed on May 3, 2019.
Prior Publication US 2022/0227853 A1, Jul. 21, 2022
Int. Cl. C07K 16/20 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 33/06 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); C12N 1/20 (2006.01); C12N 15/00 (2006.01); G01N 33/53 (2006.01); G01N 33/569 (2006.01)

CPC C07K 16/205 (2013.01) [A61K 47/6843 (2017.08); A61P 33/06 (2018.01); G01N 33/56905 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/445 (2013.01); G01N 2469/10 (2013.01); G01N 2800/26 (2013.01)]

31 Claims

1. An isolated monoclonal antibody or an antigen binding fragment thereof, comprising:

a heavy chain variable region and a light chain variable region comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2, and a HCDR3, and a light chain complementarity determining region (LCDR) 1, a LCDR2, and a LCDR3 of the V_Hand V_Lset forth as SEQ ID NOs: 1 and 2, respectively; and

wherein the monoclonal antibody specifically binds to P. falciparum circumsporozoite protein (PfCSP) and neutralizes P. falciparum.